M
M.L.M. Lybeert
Researcher at Eindhoven University of Technology
Publications - 17
Citations - 2893
M.L.M. Lybeert is an academic researcher from Eindhoven University of Technology. The author has contributed to research in topics: Endometrial cancer & Randomized controlled trial. The author has an hindex of 13, co-authored 17 publications receiving 2697 citations.
Papers
More filters
Journal ArticleDOI
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
Carien L. Creutzberg,Wim L.J. van Putten,Peter C.M. Koper,M.L.M. Lybeert,Jan J. Jobsen,C.C. Wárlám-Rodenhuis,Karin A.J. De Winter,Ludy C.H.W. Lutgens,Alfons C.M. van den Bergh,Elzbieta van de Steen-Banasik,H Beerman,Mat van Lent +11 more
TL;DR: In this article, the authors did a multicentre prospective randomised trial to find whether postoperative pelvic radiotherapy improves locoregional control and survival for patients with stage-1 endometrial carcinoma.
Journal ArticleDOI
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
Carien L. Creutzberg,W. L. J. Van Putten,Peter C.M. Koper,M.L.M. Lybeert,J.J. Jobsen,C.C. Wárlám-Rodenhuis,K.A.J. De Winter,L.C.H.W. Lutgens,A.C.M. Van Den Bergh,E de Steen-Banasik,H Beerman +10 more
Journal ArticleDOI
Survival after relapse in patients with endometrial cancer: results from a randomized trial.
Carien L. Creutzberg,Wim L.J. van Putten,Peter C.M. Koper,M.L.M. Lybeert,Jan J. Jobsen,C.C. Wárlám-Rodenhuis,Karin A.J. De Winter,Ludy C.H.W. Lutgens,Alfons C.M. van den Bergh,Elzbieta van der Steen-Banasik,H Beerman,Mat van Lent +11 more
TL;DR: As pelvic RT was shown to improve locoregional control significantly, but without a survival benefit, its use should be limited to those patients at sufficiently high risk for recurrence in order to maximize local control and relapse-free survival.
Journal ArticleDOI
The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial.
Carien L. Creutzberg,Wim L.J. van Putten,Peter C.M. Koper,M.L.M. Lybeert,Jan J. Jobsen,C.C. Wárlám-Rodenhuis,Karin A.J. De Winter,Ludy C.H.W. Lutgens,Alfons C.M. van den Bergh,Elzbieta van der Steen-Banasik,H Beerman,Mat van Lent +11 more
TL;DR: Pelvic RT increases the morbidity of treatment in Stage I endometrial cancer, and its use in the adjuvant setting requires careful patient selection (treating those at increased risk of relapse), and the use of treatment schemes with the lowest risk of morbidity.
Journal ArticleDOI
The morbidity of treatment for patients with stage I endometrial cancer: results from a randomized trial
Carien L. Creutzberg,W. L. J. Van Putten,Peter C.M. Koper,M.L.M. Lybeert,J.J. Jobsen,C.C. Wárlám-Rodenhuis,K.A.J. De Winter,L.C.H.W. Lutgens,A.C.M. Van Den Bergh,E. Van der Steen-Banasik,H Beerman,M van Lent +11 more
TL;DR: Pelvic RT increases the morbidity of treatment in Stage I endometrial cancer, and its use in the adjuvant setting requires careful patient selection (treating those at increased risk of relapse), and the use of treatment schemes with the lowest risk of morbidity.